Obsessive-Compulsive Disorder - Pipeline Insight, 2021

This “Obsessive-compulsive disorder - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Obsessive-compulsive disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Obsessive-compulsive disorder Understanding

Obsessive-compulsive disorder: Overview

Obsessive-compulsive disorder (OCD) is a disorder in which people have recurring, unwanted thoughts, ideas or sensations (obsessions) that make them feel driven to do something repetitively (compulsions). The repetitive behaviors, such as hand washing, checking on things or cleaning, can significantly interfere with a person's daily activities and social interactions.Many people without OCD have distressing thoughts or repetitive behaviors. However, these thoughts and behaviors do not typically disrupt daily life. For people with OCD, thoughts are persistent, and behaviors are rigid. Not performing the behaviors commonly causes great distress. Many people with OCD know or suspect their obsessions are not realistic; others may think they could be true (known as limited insight). Even if they know their obsessions are not realistic, people with OCD have difficulty disengaging from the obsessive thoughts or stopping the compulsive actions.

"Obsessive-compulsive disorder - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Obsessive-compulsive disorder pipeline landscape is provided which includes the disease overview and Obsessive-compulsive disorder treatment guidelines. The assessment part of the report embraces, in depth Obsessive-compulsive disorder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Obsessive-compulsive disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Obsessive-compulsive disorder R&D. The therapies under development are focused on novel approaches to treat/improve Obsessive-compulsive disorder.

Obsessive-compulsive disorder Emerging Drugs Chapters

This segment of the Obsessive-compulsive disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Obsessive-compulsive disorder Emerging Drugs

BHV-4157: Biohaven Pharmaceuticals

Troriluzole is a new chemical entity and third-generation glutamate modulating agent that normalizes glutamate, a key neurotransmitter implicated in obsessive-compulsive disorder.Biohaven was awarded two U.S. Patents covering troriluzole, with international patents pending, all having statutory expiration dates in 2039. The primary mechanism of action of troriluzole is enhancing synaptic glutamate cycling by augmenting the expression and function of excitatory amino acid transporters (i.e., EAAT1-2) located on glial cells that play a key role in clearing glutamate from the synapse. Glutamatergic dysfunction is implicated in the pathophysiology of a broad range of disorders including OCD, Amyotrophic Lateral Sclerosis, Spinocerebellar Ataxia, Alzheimer's Disease, depression, chronic pain, and a variety of cancers. The therapeutic potential of troriluzole is supported by clinical and translational research studies.

DSP-1181: Sumitomo Dainippon Pharma

DSP-1181 is a Serotonin 1A receptor agonist being developed by Sumitomo Dainippon Pharma in collaboration with Exscientia to treat Obsessive-compulsive disorder.

Obsessive-compulsive disorder: Therapeutic Assessment

This segment of the report provides insights about the different Obsessive-compulsive disorder drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Obsessive-compulsive disorder

There are approx. 4+ key companies which are developing the therapies for Obsessive-compulsive disorder. The companies which have their Obsessive-compulsive disorder drug candidates in the most advanced stage, i.e. phase III include, Biohaven Pharmaceuticals.

Phases

This report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Obsessive-compulsive disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Obsessive-compulsive disorder: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Obsessive-compulsive disorder therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Obsessive-compulsive disorder drugs.

Obsessive-compulsive disorder Report Insights

• Obsessive-compulsive disorder Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Obsessive-compulsive disorder Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Obsessive-compulsive disorder drugs?
• How many Obsessive-compulsive disorder drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Obsessive-compulsive disorder?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Obsessive-compulsive disorder therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Obsessive-compulsive disorder and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Biohaven Pharmaceuticals
• Cannabis Science
• Octapharma
• Sumitomo Dainippon Pharma Co., Ltd.
• Amorsa Therapeutics
• Phytecs

Key Products

• Troriluzole

Research programme: cannabis extract therapeutics

• Panzyga
• DSP-1181

This product will be delivered within 2 business days.